New hope for slowing deadly lung disease progression
Disease control
Ongoing
This study is testing whether a new drug called LYT-100 can slow the decline of lung function in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. It compares LYT-100 against an existing drug (pirfenidone) and a placebo in 240 adults who haven't be…
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC